Medexus Pharmaceuticals Inc (MEDXF)
Medexus Pharmaceuticals Inc. is a Canadian pharmaceutical company with operations in Canada and the United States. The company develops and markets a broad portfolio of prescription and over-the-counter products across several therapeutic areas, including allergy, dermatology, hematology, oncology, rheumatology, and rare diseases. Its product lineup includes IXINITY for hemophilia B, Rasuvo and Metoject for rheumatoid arthritis and other autoimmune diseases, Rupall for allergy treatment, GRAFAPEX and Trecondyv for transplantation-related uses, and Gleolan for surgical visualization in glioma procedures. Medexus also sells products such as Cuvposa, Naproxen, Otixal, Trispan, Nyda, Relaxa, Oralvisc, and Calcia calcium and vitamin D products. The company was founded in 2000, was formerly known as Pediapharm Inc., and adopted its current name in December 2018. It is based in Toronto, Canada.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
OTC-MEDX.F
|
$3.57
|
-0.2% Downside
|
Fair
|
$7
|
95.5% Upside
|
Bargain
|
Good
|
0.0%
|
November 11, 2026
|
2.4x
|
1.1x
|
113.4 M
|
134.2 M
|
18.8%
|
91.7%
|
2.8
|
-599.2%
|
